PDRadiopharma announces listing of Techne® Pyrophosphate Injection on Japan National Health Insurance Drug Price List and Upcoming Market Launch

NorthStar Medical Radioisotopes and PDRadiopharma Announce Research and Development Agreement, Master Isotope Supply Agreement for Ac-225 and Contract Manufacturing and Master Services Agreement

Expansion of Insurance Coverage of AMYViD®, a PET Imaging Agent for Detecting Beta Amyloid

Our Strategic Partner, Curium Announces ECLIPSE Trial has Met Primary Endpoint, Demonstrating a Statistically Significant and Clinically Meaningful Benefit for Patients With PSMA-Positive Metastatic Castration Resistant Prostate Cancer（Curiumu）

PeptiDream Announces Upcoming Presentations, and PDRadiopharma to Exhibit at the 64th Annual Scientific Meeting of the Japanese Society of Nuclear Medicine and the 44th Annual Meeting of the Japanese Society of Nuclear Medicine Technology

PDRadiopharma Inc. Receives “Controlled Medical Device” Certification for Brain Imaging Analysis Program “AMYclz® Neuro”

PeptiDream Announces Upcoming Presentation of CA9-Targeting PD-32766 Program at the Annual Meeting of the Japan Society of Urologic Oncology（PeptiDream Inc.）

PDRadiopharma, a PeptiDream Company, and Curium Announce Strategic Partnership for the Development and Commercialization of 177Lu-PSMA-I&T and 64Cu-PSMA-I&T in Japan

Announcement of New Management Structure

Launch of Medical DX (Digital Transformation) Solutions “Bridgea TIMER Guide” and “onti-d”